Australian diagnostics company Ellume will open its first U.S. manufacturing facility in Frederick, Maryland later this year, with plans to hire 1,500 workers and eventually produce up to 19 million of its at-home Covid-19 tests there every month.
Brisbane-based Ellume announced it will build two manufacturing facilities totaling more than 180,000 square feet at 4930 Executive Court South in Frederick. The facilities will be developed by Frederick-based Matan Progress Labs as part of its Progress Labs at Center 85 project, which is part of Matan’s larger build-out of biomanufacturing-ready space along the Interstate 270 corridor in Frederick and Montgomery counties. The facility will begin limited production of Ellume’s at-home Covid-19 tests in the second half of 2021, with plans to continue scaling up capacity through the rest of the year.
In December, Ellume’s home Covid-19 tests became the first to be granted emergency use authorization by the U.S. Food and Drug Administration for asymptomatic and symptomatic use without a prescription. In February, Ellume struck a $231.8 million agreement with the U.S. Department of Defense and the Department of Health and Human Services to ramp up production of the at-home tests. The contract included funding to support a U.S. manufacturing facility as well as an agreement to provide 8.5 million at-home tests to the U.S. government by the end of the year. Ellume also began selling its tests at CVS Pharmacy last month at a cost of $38.99 each.